TD Cowen analyst Tyler Van Buren has maintained their bullish stance on BBIO stock, giving a Buy rating on April 15.
Tyler Van Buren’s rating is based on several factors, including the anticipation of BridgeBio Pharma slightly exceeding expectations in their Q1 performance. The company is expected to show strong week-over-week growth in prescriptions, which has led to an increase in the estimated revenue from $10 million to $12 million.
Despite a slight rise in R&D expenses by $5 million, the overall earnings per share (EPS) for the quarter is projected to remain at ($0.80). These factors combined contribute to the confidence in maintaining a Buy rating for BridgeBio Pharma.
In another report released on April 15, Bank of America Securities also reiterated a Buy rating on the stock with a $46.00 price target.